SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

“Hmmm” is a community meme token on the Solana network, launched on July 22, 2024, through Pumpfun. It’s a derivative of Pepe the Frog but has evolved into its own distinct meme with a unique identity. The token embraces the humor and intrigue of internet culture, playing on the idea of curiosity and speculation. “Hmmm” captures a playful approach to the world of meme tokens, designed to engage a community driven by fun and the whimsical side of crypto. Hmmm, maybe this’ll send.

hmmm

The crypto token $HMMM is gaining attention, with many users discussing its potential and availability on Phantom Wallet. Community members are using terms like "rocket," "moon," and "gem" to describe the token's momentum. Some users are also speculating about the driving forces behind the recent price action.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto ($CLANKER) is trending as traders discuss its potential Coinbase listing and the impact on its price. The community is focused on its limited supply of 1 million coins, speculating on possible price movements and 

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is gaining traction as a community-driven token with viral hype, trending on Stocktwits with serious volume. The community emphasizes its strength and unity, rallying behind upcoming events like Karolina Arm's sponsored fight. Discussions highlight $SLAP's ambition to become a global brand, transcending its meme origins through real-world partnerships and a dedicated community.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as community members discuss its potential in the expanding play-to-earn and virtual world sectors, focusing on its technology that bridges blockchain with gaming. Conversations highlight the growing community, new exchange listings, and its potential within the AI and blockchain space. Some traders are also taking profits from other tokens and moving them into Virtual Protocol.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the community debates its future following FDA approval of Tonmya, with discussions focused on potential sales, upcoming catalysts, and whether the stock is undervalued. Some traders express frustration with management and the stock's performance, while others remain optimistic about long-term growth and potential short squeezes. BlackRock's increased stake is being viewed as a potential bullish signal amid the ongoing volatility.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as traders discuss its low market cap and circulating supply, anticipating a potential breakout. Some community members point to its integration with Aleph Zero, while others speculate about possible listings on major exchanges like Binance as a catalyst for significant gains. Technical analysis chatter includes mentions of oversold RSI conditions and bull flag formations.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to news of a potential shakeup in the Alzheimer's space following a recent investment in Vanqua Bio, which has investors speculating about Biogen's strategy around C5aR1 inhibitors, a target also being pursued by InflaRx ($IFRX). The community is analyzing the implications of Biogen's move for InflaRx's valuation and potential acquisition, viewing it as both mechanistic validation and a catalyst for sentiment. There is also discussion around Biogen's earnings and growth prospects, especially concerning new therapies offsetting multiple sclerosis portfolio weakness.

Columbus Circle Capital Corp. I operates as a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which refer to throughout this prospectus as initial business combination. The company was founded in June 2024 and is headquartered in New York, NY.

Columbus Circle Capital Corp I - Ordinary Shares - Class A

Columbus Circle Capital ($BRR) is trending as the community discusses Eric Jackson joining the board and anticipates a potential pump, drawing comparisons to past option surges. Chatter revolves around upcoming call options and a proposed merger with ProCap BTC, with some seeing a potentially favorable risk-reward scenario due to the SPAC's NAV floor. Recent news includes updates to the merger agreement and the appointment of a new CFO.

Codatta

Codatta ($XNY) is trending as the community discusses its potential breakout, with some suggesting it's building towards a significant move. Many traders are watching its correlation with Bitcoin ($BTC), anticipating a surge if $BTC breaks resistance. Technical analysis is being shared, highlighting bullish formations and key support levels.

KraneShares Trust - KraneShares Global Humanoid and Embodied Intelligence Index ETF

KraneShares Global Humanoid and Embodied Intelligence Index ETF

$KOID is trending as discussions emerge around robotics and AI, specifically humanoid robots. Community members are actively comparing $KOID to other robotics ETFs and discussing the potential impact of Chinese investment in the sector, with some noting the fund's growing exposure and potential for long-term growth. Mentions of Elon Musk's views on robotics and humanoid development are also contributing to the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SciSparc (SPRC) announced on Monday that it has decided to terminate the proposed merger with AutoMax Motors.SciSparc <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161557/0/en/SciSparc-Ltd-Announces-Framework-Agreement-Regarding-Merger-with-AutoMax-Motors.html">announced</a> that the decision was mutual, and the merger agreement is null, effective immediately. The two companies also established clear repayment terms for SciSparc’s existing loans to AutoMax, totaling a principal amount of $6.25 million. The companies did not provide a reason for scrapping the proposed merger.SPRC shares traded 2% higher at the time of writing. Scisparc stated that AutoMax will repay $4.25 million in principal, with interest, in a single lump sum payment on Jan. 1, 2028, and another $2 million in principal, with interest, in monthly installments starting Nov. 20, 2025. All accrued interest will be paid at the outset, the company added.Late in August, the pharmaceutical company said that its shareholders approved its proposed merger with AutoMax, a parallel vehicle importer in Israel. The two companies entered into a definitive agreement in April 2024, under which SciSparc would acquire 100% of AutoMax’s share capital by way of a reverse merger between SciSparc Merger Sub, a wholly owned subsidiary of the company, and AutoMax, with AutoMax continuing as a wholly owned subsidiary of SciSparc. The proposed merger was aimed at diversifying SciSparc’s portfolio and capitalizing on the expanding electric vehicle market in Israel.SciSparc is currently focused on a portfolio based on cannabinoid pharmaceuticals. It is developing drugs for the treatment of Tourette Syndrome, Alzheimer’s disease, and Autistic Spectrum Disorders (ASD), among others.&nbsp;SPRC stock is down 37% this year but is up approximately 3% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SciSparc And AutoMax Motors Scrap Proposed Merger

The decision was mutual, and the merger agreement is null, effective immediately, SciSparc said.

Equity

The decision was mutual, and the merger agreement is null, effective immediately, SciSparc said.


SciSparc’s (SPRC) shares soared over 61% on Thursday after the company announced its plans to launch an initiative to advance 3D protein modeling using quantum computing technology.SciSparc <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/25/3156166/0/en/SciSparc-Resolves-to-Launch-Innovative-Quantum-Computing-Enabled-3D-Protein-Modeling-Initiative-to-Revolutionize-AI-Drug-Discovery.html">will</a> form a dedicated research team to integrate quantum computing algorithms into 3D protein modeling to create new intellectual property. Initial efforts will focus on refining quantum algorithms to simulate protein dynamics and binding interactions, with the goal of targeting applications in drug discovery for neurological and rare diseases. SciSparc also said that it expects to incorporate a new wholly owned Israeli subsidiary, which will operate the initiative.The firm explained that knowing a protein’s three-dimensional structure is key to understanding how it interacts in the body and how to design effective drugs. Scientists typically use computers to predict the 3D structure. However, the process has its challenges, including the dynamic nature of proteins, which involves constantly shifting between different conformations, SciSparc said.Quantum computing may simulate the energy dynamics of proteins with greater precision, capturing their complex movements and interactions with potential drugs with much higher accuracy, the company said. The firm expressed optimism that this may pave the way for breakthroughs in structural biology and personalized medicine.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRC">SPRC stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_12_19_35_PM_png_a67dccb366.webp" alt="SPRC's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="576" height="64"><figcaption>SPRC's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to hit $10 by the end of the day.<stembedurl>https://stocktwits.com/Proecadguy/message/629996574</stembedurl>Late last month, the company said that its shareholders approved its proposed merger with AutoMax Motors, a parallel vehicle importer in Israel. Following the closing of the merger, SciSparc shareholders are expected to hold approximately 50.01% of the combined company’s share capital. However, the merger's closing is subject to approval by the Israeli court.SPRC stock is down approximately 19% this year and up about 18% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/carmax-stock-tumbles-after-q2-earnings/chDlO6OR348">Why Did CarMax Stock Tumble 24% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

SciSparc Stock Soared 61% Today – Here’s An Important Update

The company will establish a dedicated research team to integrate quantum computing algorithms into 3D protein modeling, aiming to create new intellectual property.

Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome

SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon.
read more...

Clearmind Medicine Files International Patent For Ibogaine Combination Therapy

Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.
read more...

SciSparc and Clearmind Innovate in Mental Health Therapy

SciSparc Ltd. (SPRC) has released an update. SciSparc Ltd., a pharmaceutical company specializing in central nervous system disorders, has revealed...

SciSparc Initiates Groundbreaking Autism Therapy Trial

SciSparc Ltd. (SPRC) has released an update. SciSparc Ltd., a pharmaceutical firm focused on central nervous system disorders, has launched a clini...

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

SciSparc signs an exclusive license agreement with Polyrizon Ltd for its SCI-160 pain treatment program, with potential milestones of $3M in cash plus royalties.
read more...

SciSparc Eyes $6M Deal for Pain Treatment License

SciSparc Ltd. (SPRC) has released an update. SciSparc Ltd., a clinical-stage pharmaceutical company, has announced a non-binding letter of intent t...

SciSparc Ltd. Faces Nasdaq Delisting Over Bid Price

SciSparc Ltd. (SPRC) has released an update. SciSparc Ltd., a biopharmaceutical firm focusing on central nervous system disorders, has been notifie...

SciSparc says Clearmind submits international patent application for depression

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. It operates through the Drug Development and Online Sales segments. The Drug Development segment focuses on cannabinoid molecules to be approved by an official regulatory authority. The Online Sales segment consists of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

SciSparc Ltd

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$4.02
Prev Close	$3.98
Open	$4.08
Dividend Yield	0.00%
50-Day Moving Average	$3.83
Beta	0.74
Avg. Volume	13.07M
PE Ratio	-0.10

52-Week High	$37.59
52-Week Low	$1.75
Market Capitalization	$6.52M
EPS (Annual)	-$22.65
Price to Book	0.25
Revenue Per Employee	$653,000.00
Enterprise Value/EBITDA	N/A

SPRC
Scisparc Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest SPRC News

SPRCScisparc Ltd